DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11

Epigenetics

Volumn 8, Issue 8, 2013, Pages 849-863

  James, Smitha R ^a,d   Cedeno, Carlos D ^a   Sharma, Ashok ^b   Zhang, Wa ^a,b   Mohler, James L ^a   Odunsi, Kunle ^a   Wilson, Elizabeth M ^c   Karpf, Adam R ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cancer germline genes; Cancer testis genes; DNA methylation; Epigenetics; MAGEA11; Nucleosome occupancy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 11; MITHRAMYCIN; NY ESO1 ANTIGEN; RNA POLYMERASE II; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A; TUMOR ANTIGEN; UNCLASSIFIED DRUG; XAGE1 ANTIGEN;

ALLELE; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC REGULATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOSOME; OVARY CARCINOMA; PROSTATE CANCER; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

CANCER GERMLINE GENES; CANCER TESTIS GENES; DNA METHYLATION; EPIGENETICS; MAGEA11; NUCLEOSOME OCCUPANCY;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEOSOMES; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SP1 TRANSCRIPTION FACTOR;

EID: 84880973690     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.25500     Document Type: Article

References (67)

1. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol 2010; 6:717-32; PMID:20465387
2. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615-25; PMID:16034368
3. Meek DW, Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett 2012; 324:126-32; PMID:22634429
4. Minges JT, Su S, Grossman G, Blackwelder AJ, Pop EA, Mohler JL, et al. Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers. J Biol Chem 2013; 288:1939-52; PMID:23172223
5. Liu W, Cheng S, Asa SL, Ezzat S. The melanomaassociated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008; 68:8104-12; PMID:18829569
6. Cappell KM, Sinnott R, Taus P, Maxfield K, Scarbrough M, Whitehurst AW. Multiple cancer testis antigens function to support tumor cell mitotic fidelity. Mol Cell Biol 2012; 32:4131-40; PMID:22869527
7. Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik JT, Larson B, et al. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res 2010; 70:7652-61; PMID:20876808
8. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007; 446:815-9; PMID:17429401
9. Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon YW, Bosman FT, et al. BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res 2011; 39:862-73; PMID:20876690
10. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009; 7:523-35; PMID:19372581
11. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1:239-59; PMID:20495664
12. Karpf AR. Epigenetic alterations in oncogenesis. Preface. Adv Exp Med Biol 2013; 754:v-vii; PMID:23189391
13. Cannuyer J, Loriot A, Parvizi GK, De Smet C. Epigenetic hierarchy within the MAGEA1 cancergermline gene: promoter DNA methylation dictates local histone modifications. PLoS One 2013; 8:e58743; PMID:23472218
14. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006; 25:6975-85; PMID:16715135
15. Link PA, Gangisetty O, James SR, Woloszynska-Read A, Tachibana M, Shinkai Y, et al. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol Cancer Res 2009; 7:851-62; PMID:19531572
16. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1,-A2,-A3, and-A12 in human cancer cells. Mol Cancer Res 2006; 4:339-49; PMID:16687489
17. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol 2004; 65:18-27; PMID:14722233
18. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007; 7:21; PMID:18095639
19. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res 2008; 14:3283-90; PMID:18519754
20. Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011; 17:2170-80; PMID:21296871
21. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416:552-6; PMID:11932749
22. Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem 2005; 77:504-10; PMID:15649046
23. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, et al. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 2011; 71:4192-204; PMID:21546573
24. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265:17174-9; PMID:2211619
25. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457-63; PMID:15164071
26. Campbell MJ, Turner BM. Altered histone modifications in cancer. Adv Exp Med Biol 2013; 754:81-107; PMID:22956497
27. De Plaen E, Naerhuyzen B, De Smet C, Szikora JP, Boon T. Alternative promoters of gene MAGE4a. Genomics 1997; 40:305-13; PMID:9119398
28. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genomewide demethylation. Proc Natl Acad Sci U S A 1996; 93:7149-53; PMID:8692960
29. Li L, Davie JR. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 2010; 192:275-83; PMID:20810260
30. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 1991; 88:1613-21; PMID:1834700
31. Henikoff S. Nucleosomes at active promoters: unforgettable loss. Cancer Cell 2007; 12:407-9; PMID:17996642
32. Pondugula S, Kladde MP. Single-molecule analysis of chromatin: changing the view of genomes one molecule at a time. J Cell Biochem 2008; 105:330-7; PMID:18615586
33. Miranda TB, Kelly TK, Bouazoune K, Jones PA. Methylation-sensitive single-molecule analysis of chromatin structure. Current protocols in molecular biology/ edited by Frederick M Ausubel [et al.] 2010; Chapter 21:Unit 21 17 1-6.
34. You JS, Kelly TK, De Carvalho DD, Taberlay PC, Liang G, Jones PA. OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. Proc Natl Acad Sci U S A 2011; 108:14497-502; PMID:21844352
35. Jessen WJ, Dhasarathy A, Hoose SA, Carvin CD, Risinger AL, Kladde MP. Mapping chromatin structure in vivo using DNA methyltransferases. Methods 2004; 33:68-80; PMID:15039089
36. Pardo CE, Darst RP, Nabilsi NH, Delmas AL, Kladde MP. Simultaneous single-molecule mapping of protein-DNA interactions and DNA methylation by MAPit. Current protocols in molecular biology/edited by Frederick M Ausubel [et al.] 2011; Chapter 21:Unit 212.
37. Pardo CE, Carr IM, Hoffman CJ, Darst RP, Markham AF, Bonthron DT, et al. MethylViewer: computational analysis and editing for bisulfite sequencing and methyltransferase accessibility protocol for individual templates (MAPit) projects. Nucleic Acids Res 2011; 39:e5; PMID:20959287
38. Bai L, Morozov AV. Gene regulation by nucleosome positioning. Trends Genet 2010; 26:476-83; PMID:20832136
39. Bai S, He B, Wilson EM. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 2005; 25:1238-57; PMID:15684378
40. Jurk M, Kremmer E, Schwarz U, Förster R, Winnacker EL. MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus. Int J Cancer 1998; 75:762-6; PMID:9495246
41. Su S, Blackwelder AJ, Grossman G, Minges JT, Yuan L, Young SL, et al. Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation. J Biol Chem 2012; 287:34809-24; PMID:22891251
42. Askew EB, Bai S, Blackwelder AJ, Wilson EM. Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J Biol Chem 2010; 285:21824-36; PMID:20448036
43. Su S, Minges JT, Grossman G, Blackwelder AJ, Mohler JL, Wilson EM. Proto-oncogene activity of Melanoma antigen-A11 (MAGE-A11) regulates Retinoblastomarelated p107 and E2F1. J Biol Chem 2013; In press.
44. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear laminaassociated domains. Nat Genet 2012; 44:40-6; PMID:22120008
45. Reddy KL, Feinberg AP. Higher order chromatin organization in cancer. Semin Cancer Biol 2013; 23:109-15; PMID:23266653
46. Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006; 1:116-20; PMID:17786175
47. Pandiyan K, You JS, Yang X, Dai C, Zhou XJ, Baylin SB, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res 2013; 41:3973-85; PMID:23408854
48. Portela A, Liz J, Nogales V, Setién F, Villanueva A, Esteller M. DNA methylation determines nucleosome occupancy in the 5'-CpG islands of tumor suppressor genes. Oncogene 2013; PMID:23686312
49. Bi FF, Li D, Yang Q. Hypomethylation of ETS Transcription Factor Binding Sites and Upregulation of PARP1 Expression in Endometrial Cancer. Biomed Res Int 2013; 2013:946268; PMID:23762867
50. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 2011; 80:437-71; PMID:21548782
51. Harrington MA, Jones PA, Imagawa M, Karin M. Cytosine methylation does not affect binding of transcription factor Sp1. Proc Natl Acad Sci U S A 1988; 85:2066-70; PMID:3281160
52. Höller M, Westin G, Jiricny J, Schaffner W. Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated. Genes Dev 1988; 2:1127-35; PMID:3056778
53. Clark SJ, Harrison J, Molloy PL. Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 1997; 195:67-71; PMID:9300822
54. Mancini DN, Singh SM, Archer TK, Rodenhiser DI. Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. Oncogene 1999; 18:4108-19; PMID:10435592
55. Mulero-Navarro S, Carvajal-Gonzalez JM, Herranz M, Ballestar E, Fraga MF, Ropero S, et al. The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding. Carcinogenesis 2006; 27:1099-104; PMID:16410262
56. Butler JE, Kadonaga JT. The RNA polymerase II core promoter: a key component in the regulation of gene expression. Genes Dev 2002; 16:2583-92; PMID:12381658
57. Darst RP, Pardo CE, Pondugula S, Gangaraju VK, Nabilsi NH, Bartholomew B, et al. Simultaneous singlemolecule detection of endogenous C-5 DNA methylation and chromatin accessibility using MAPit. Methods Mol Biol 2012; 833:125-41; PMID:22183592
58. Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC, et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007; 12:432-44; PMID:17996647
59. Delmas AL, Riggs BM, Pardo CE, Dyer LM, Darst RP, Izumchenko EG, et al. WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis 2011; 32:1625-33; PMID:21873353
60. Kilgore JA, Hoose SA, Gustafson TL, Porter W, Kladde MP. Single-molecule and population probing of chromatin structure using DNA methyltransferases. Methods 2007; 41:320-32; PMID:17309843
61. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7:64; PMID:17430594
62. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, et al. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 2006; 4:79-92; PMID:16513839
63. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365
64. Hu N, Clifford RJ, Yang HH, Wang C, Goldstein AM, Ding T, et al. Genome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinoma. BMC Genomics 2010; 11:576; PMID:20955586
65. Aoyagi K, Minashi K, Igaki H, Tachimori Y, Nishimura T, Hokamura N, et al. Artificially induced epithelialmesenchymal transition in surgical subjects: its implications in clinical and basic cancer research. PLoS One 2011; 6:e18196; PMID:21533028
66. Cutcliffe C, Kersey D, Huang CC, Zeng Y, Walterhouse D, Perlman EJ; Renal Tumor Committee of the Children's Oncology Group. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 2005; 11:7986-94; PMID:16299227
67. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 2006; 3:e13; PMID:16318415